Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro

被引:72
作者
Christiansen, Anne [1 ,2 ]
Backensfeld, Thomas [2 ]
Denner, Karsten [3 ]
Weitschies, Werner [1 ]
机构
[1] Ernst Moritz Arndt Univ Greifswald, Dept Biopharmaceut & Pharmaceut Technol, D-17487 Greifswald, Germany
[2] Bayer Schering Pharma AG, Analyt Dev, Berlin, Germany
[3] Dept Drug Metab & Pharmacokinet, Berlin, Germany
关键词
Non-ionic surfactants; Excipients; Inhibition effect; Cytochrome P450; Intestinal metabolism; Bioavailability; P-GLYCOPROTEIN; PHARMACEUTICAL EXCIPIENTS; ORAL DELIVERY; ABSORPTION; IMPACT; 3A4; BIOAVAILABILITY; CLASSIFICATION; FORMULATIONS; MECHANISM;
D O I
10.1016/j.ejpb.2010.12.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of the study was to investigate the impact of commonly used non-ionic surfactants on cytochrome P450 (CYP) 3A4-mediated metabolism of testosterone and the CYP2C9-mediated metabolism of diclofenac. Polysorbate 80 (PS 80), D-alpha-tocopheryl polyethylene glycol (1000) succinate (TPGS), sucrose laurate, Cremophor EL (CR EL), and Cremophor RH 40 (Cr RH 40) were incubated with human liver microsomes at different concentrations to determine the IC50 of the reduced metabolism of the model substrates. Inhibitory potential in case of all tested compounds could be observed already below their critical micelle concentrations (CMC) and in concentration-dependant manner. The IC50 of the CYP 3A4-mediated 6 beta-hydroxylation of testosterone has been determined as 0.40 mM (PS 80), 0.15 mM (TPGS), 0.20 mM (sucrose laurate), 0.60 mM (Cr EL), and 0.80 mM (Cr RH 40). The IC50 concerning the CYP 2C9-mediated 4-hydroxylation of diclofenac has been calculated to be 0.04 mM (PS 80), 0.30 mM (TPGS), 0.07 mM (sucrose laurate), 0.03 mM (Cr EL), and 0.03 mM (Cr RH 40). The results indicate that these non-ionic surfactants are in vitro inhibitors of CYP-mediated metabolism and might have the potential to modify the pharmacokinetics of co-administered drugs, which are substrates of CYP, and thereby enhance their bioavailability. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 41 条
[1]  
ANTON A, 2004, EFSA J, V106, P1
[2]   The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin [J].
Backman, JT ;
Kivistö, KT ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) :53-58
[3]  
Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
[4]  
CHRISTIANSEN A, J PHARM SCI UNPUB
[5]   Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes [J].
Christiansen, Anne ;
Backensfeld, Thomas ;
Weitschies, Werner .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 41 (02) :376-382
[6]   Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo [J].
Cornaire, G ;
Woodley, J ;
Hermann, P ;
Cloarec, A ;
Arellano, U ;
Houin, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 278 (01) :119-131
[7]   Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs [J].
Cuine, Jean F. ;
McEvoy, Claire L. ;
Charman, William N. ;
Pouton, Colin W. ;
Edwards, Glenn A. ;
Benameur, Hassan ;
Porter, Christopher J. H. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (02) :995-1012
[8]  
ERIN DH, 2002, J PHARM SCI, V91, P1980
[9]   Monocomponent hexa- and dodecaethylene glycol succinyl-tocopherol esters: Self-assembly structures, cellular uptake and sensitivity to enzyme hydrolysis [J].
Folmer, Britta M. ;
Barron, Denis ;
Hughes, Eric ;
Miguet, Laurence ;
Sanchez, Belen ;
Heudi, Olivier ;
Rouvet, Martine ;
Sagalowicz, Laurent ;
Callier, Philippe ;
Michel, Martin ;
Williamson, Gary .
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (12) :1464-1474
[10]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19